CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants
The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Over 40 cytochrome P450 (CYP) 2D6 allelic variants have been discovered thus far. The alleles may be classified on the basis of the level of activity for which they encode CYP2D6 enzymes, into functional, non-functional and reduced function groups. CYP2D6 allele frequency is known to vary amongst racial/ethnic groups. Generally, for European Caucasians and their descendants, the functional group of alleles are predominant, with a frequency of 71%. Non-functional alleles represent 26% of the variability, mainly CYP2D6*4. In Asians and their close descendants, functional alleles represent only ~ 50% of the frequency of CYP2D6 alleles. Asians and Pacific Islanders have a high frequency (median = 41%) of a reduced function allele, CYP2D6*10, contributing to the population shift to the right of metabolic rates indicating slower metabolism. Information concerning Amerindians from North (Canada), Central and South America indicate comparatively low frequencies of CYP2D6*10, perhaps a "founders" effect. The frequency of functional alleles in Africans and African Americans is also about 50%. Both Africans and African Americans have reduced function alleles representing 35% of allele variation, mainly CYP2D6*17. African Americans, however, have more than twice the median frequency of nonfunctional alleles compared with Africans (14.5% vs 6.3%). Non-functional and reduced function alleles represent about 50% of allele frequency in Black populations but a much greater variety than carried in Asians. Since alleles which encode for no or reduced functioning clearly affect metabolic activity of drugs mediated by CYP2D6, studies are needed in populations in which these alleles play a major role in order to assure optimal dosing recommendations are based on empirical pharmacogenetics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,782
The History and Geography of Human Genes: Abridged paperback Edition
Cavalli-Sforza, L. L., Menozzi, P., & Piazza, A. (2018) · Princeton University Press eBooks · doi:10.2307/j.ctv301gjp · Cited by 3,175
Sachse, C., Brockmöller, J., Bauer, S., & Roots, I. (1997) · Europe PMC (PubMed Central) · Cited by 973
MOLECULAR MECHANISMS OF GENETIC POLYMORPHISMS OF DRUG METABOLISM
Meyer, U. A., & Zanger, U. M. (1997) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.37.1.269 · Cited by 549
Bertilsson, L. (1995) · Clinical Pharmacokinetics · doi:10.2165/00003088-199529030-00005 · Cited by 432
Johansson, I., Oscarson, M., Yue, Q. Y., Bertilsson, L., Sjöqvist, F., & Ingelman-Sundberg, M. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09721-4 · Cited by 430
Bertilsson, L., Lou, Y.-Q., Du, Y.-L., Liu, Y., Kuang, T.-Y., Liao, X.-M., Wang, K.-Y., Reviriego, J., Iselius, L., & Sjöqvist, F. (1992) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1992.38 · Cited by 399
Nomenclature for human CYP2D6 alleles
Daly, A. K., Brockmoller, J., Broly, F., Eichelbaum, M., Evans, W. E., Gonzalez, F. J., Huang, J. D., Idle, J. R., Ingelman-Sundberg, M., Ishizaki, T., et al. (1996) · Pharmacogenetics · doi:10.1097/00008571-199606000-00001 · Cited by 396
Aklillu, E., Persson, I., Bertilsson, L., Johansson, I., Rodrigues, F., & Ingelman-Sundberg, M. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20152-5 · Cited by 392
Marez, D., Legrand, M., Sabbagh, N., Lo Guidice, J.-M., Spire, C., Lafitte, J.-J., Meyer, U. A., & Broly, F. (1997) · Pharmacogenetics · doi:10.1097/00008571-199706000-00004 · Cited by 380
Cited by
Ingelman-Sundberg, M. (2005) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500285 · Cited by 1,108
(2007) · PubMed · Cited by 953
Jin, Y., Desta, Z., Stearns, V., Ward, B., Ho, H., Lee, K.-H., Skaar, T., Storniolo, A. M., Li, L., Araba, A., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji005 · Cited by 951
Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance: Part I
Zhou, S.-F. (2009) · Clinical Pharmacokinetics · doi:10.2165/11318030-000000000-00000 · Cited by 756
Kirchheiner, J., Nickchen, K., Bauer, M., Wong, M.-L., Licinio, J., Roots, I., & Brockmöller, J. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001494 · Cited by 724
Genetic variation, classification and ‘race’
Jorde, L. B., & Wooding, S. P. (2004) · Nature Genetics · doi:10.1038/ng1435 · Cited by 637
“The median frequencies of null CYP2D6 alleles vary from 6% in Asian populations to 7% in African populations and 26% in European population”
BackgroundHerb-Drug Interactions: A Literature Review
Hu, Z., Yang, X., Ho, P. C. L., Chan, S. Y., Heng, P. W. S., Chan, E., Duan, W., Koh, H. L., & Zhou, S. (2005) · Drugs · doi:10.2165/00003495-200565090-00005 · Cited by 633
Albain, K. S., Unger, J. M., Crowley, J. J., Coltman, C. A., & Hershman, D. L. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp175 · Cited by 458
Sistonen, J., Sajantila, A., Lao, O., Corander, J., Barbujani, G., & Fuselli, S. (2007) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000239974.69464.f2 · Cited by 398
Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine
Ahmed, S., Zhou, Z., Zhou, J., & Chen, S.-Q. (2016) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2016.03.008 · Cited by 371
Applications of CYP450 Testing in the Clinical Setting
Samer, C. F., Lorenzini, K. I., Rollason, V., Daali, Y., & Desmeules, J. A. (2013) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-013-0028-5 · Cited by 354
Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research
Arranz, M. J., & de Leon, J. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002009 · Cited by 351
Racial/ethnic differences in drug disposition and response: Review of recently approved drugs
Ramamoorthy, A., Pacanowski, M., Bull, J., & Zhang, L. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.61 · Cited by 341
CYP2D6 and tamoxifen: DNA matters in breast cancer
Hoskins, J. M., Carey, L. A., & McLeod, H. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2683 · Cited by 322
Drug-induced QT interval prolongation: mechanisms and clinical management
Nachimuthu, S., Assar, M. D., & Schussler, J. M. (2012) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098612454283 · Cited by 307
Use of Opioids for Adults With Pain From Cancer or Cancer Treatment: ASCO Guideline
Paice, J. A., Bohlke, K., Barton, D., Craig, D. S., El-Jawahri, A., Hershman, D. L., Kong, L. R., Kurita, G. P., LeBlanc, T. W., Mercadante, S., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02198 · Cited by 304
de Leon, J., Armstrong, S. C., & Cozza, K. L. (2006) · Psychosomatics · doi:10.1176/appi.psy.47.1.75 · Cited by 300
Polymorphic Cytochrome P450 Enzymes (CYPs) and Their Role in Personalized Therapy
Preissner, S. C., Hoffmann, M. F., Preissner, R., Dunkel, M., Gewiess, A., & Preissner, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082562 · Cited by 278
Drug‐ and non‐drug‐associated QT interval prolongation
Van Noord, C., Eijgelsheim, M., & Stricker, B. H. C. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03660.x · Cited by 264
CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients
Rae, J. M., Drury, S., Hayes, D. F., Stearns, V., Thibert, J. N., Haynes, B. P., Salter, J., Sestak, I., Cuzick, J., & Dowsett, M. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs126 · Cited by 259
Pharmacokinetic Interactions of Drugs with St John’s Wort
Zhou, S., Chan, E., Pan, S.-Q., Huang, M., & Lee, E. J. D. (2004) · Journal of Psychopharmacology · doi:10.1177/0269881104042632 · Cited by 253
The Residual Medium and Long-term Cognitive Effects of Benzodiazepine Use: An Updated Meta-analysis
Crowe, S. F., & Stranks, E. K. (2018) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/acx120 · Cited by 209
Blood biomarkers and treatment response in major depression
Mora, C., Zonca, V., Riva, M. A., & Cattaneo, A. (2018) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2018.1470927 · Cited by 107
“people is the CYP2D6*4 (allele frequency 20%) and it has been associated with a poor metabolizer phenotype [33].”
BackgroundChoi, H. Y., Bae, K.-S., Cho, S.-H., Ghim, J.-L., Choe, S., Jung, J. A., Jin, S.-J., Kim, H.-S., & Lim, H.-S. (2015) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000176 · Cited by 49
Pharmacogenomic Biomarkers and Their Applications in Psychiatry
Kam, H., & Jeong, H. (2020) · Genes · doi:10.3390/genes11121445 · Cited by 37
“Thus, a large proportion of Asians belong to intermediate metabolizers than Caucasians [30].”
BackgroundInfluentialBoun, S. S., Omonaiye, O., & Yaya, S. (2024) · PLOS Global Public Health · doi:10.1371/journal.pgph.0002784 · Cited by 22
Jimenez, N., & Galinkin, J. L. (2015) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000000721 · Cited by 21
Metadata
- Authors
- Bradford, L. D.
- Venue
- Pharmacogenomics
- Publisher
- Informa UK Limited
- Published
- 2002-03
- Volume
- 3
- Issue
- 2
- Pages
- 229-243
- ISSN
- 1462-2416 (ISSN-L)
- 1744-8042
- OpenAlex
- W2098867544
- Cited by
- 773
- References
- 38
- FWCI
- 14.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.